NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week was full of exciting news. Genmab announced better-than-expected sales numbers for Darzalex at close to USD 2.7 billion, Expres2ion completed a GLP safety study, Evaxion completed dosing of the first patient in a study, Curasight got approval to start a new study with Curium, and Pila Pharma announced a new chairman and CEO. The best stock of the week rose almost 300%.

10 of the 21 Danish companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Gubra is now the best-performing Danish healthcare stock year-to-date with a 126% return and Pila Pharma was the best Nordic healthcare investment last week.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Acarix

No news the past week

Ascendis Pharma

No news the past week

Biosergen

Conversion of paid subscribed units and first day of trading with warrants of series TO3 (Link)

Cessatech

A short business update (Link)

CS Medica

No news the past week

Curasight

Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients (Link)

Evaxion Biotech

Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01 (Link)

ExpreS2ion

ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate (Link)

Fluoguide

No news the past week

Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 (Link)

Gubra

Gubra unveils UCN2 as novel anti-obesity drug candidate for healthy weight loss (Link)

Initiator Pharma

No news the past week

IO Biotech

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness (Link)

Pila Pharma

Pila Pharma AB appoints new chairman of the board and CEO (Link)

Saniona

No news the past week

Scandion Oncology

Scandion Oncology carries out a rights issue of approximately SEK 60 million secured up to approximately SEK 30.6 million (Link)

SynAct Pharma

No news the past week

ViroGates

ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA (Link)

Zealand Pharma

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (Link)

Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 (Link)

Y-mAbs Therapeutics

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer (Link)

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of 0.8%. Pila Pharma rose 50%. There was a steady increase throughout the week thus it can not be attributed to the announcement end week of the founder changing the role as CEO to BoD and CSO. Expres2ion rose 24% following the completion of a GLP safety study for a breast cancer vaccine. The Evaxion stock increased 5% after the first patient completed dosing for the vaccine EVX-01, while Curasight ended up flat for the week after they received approval for a clinical trial application for a phase 2 study with Curium for uTRACE in prostate cancer. Finally, Genmab fell 3% although they announced better-than-expected sales numbers for Darzalex at MUSD 2692 in Q1.

The best stocks year-to-date continue to be Y-mAbs Therapeutics and Gubra with 122-126% increases after the first 3.5 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 4.5%.

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 2.1% to 59.36. The index was recovering from its all-time low in October of 57.12 but has since been on a downward trajectory towards the all-time low again. In the past 12 months, the index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

50–282% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Eurocine Vaccines AB (282%)  operates in the pharmaceutical industry with a focus on developing vaccines for the global market. The company develops vaccine candidates from early innovation and licenses them to partners for further development and commercialization. The rise happened following the announcement of the plans to carry out a reverse acquisition of Nidhogg Resources AB (Link)

European Institute of Science AB (113%) focuses on the development of diagnostic analyses used for clinical laboratory and point-of-care settings, primarily in veterinary health for dog, cat, and equine animals.

Pila Pharma AB (50%) operates in the pharmaceutical industry. The company conducts clinical trials in phase 2 with pharmaceuticals for type 2 diabetes. The main product is a tablet that is taken orally at an early stage of diabetes to restore the body’s insulin production and thereby reduce the patient’s blood sugar level. As previously said, in the past week, the company announced changes to the chairman and CEO positions.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites